Safety and Efficacy of Topical Lovastatin Plus Cholesterol Cream vs Topical Lovastatin Cream Alone for the Treatment of Disseminated Superficial Actinic Porokeratosis: A Randomized Clinical Trial

洛伐他汀 医学 随机对照试验 皮肤病科 临床试验 不利影响 异维甲酸 内科学 外科 胆固醇 痤疮
作者
Gabriella Santa Lucia,Alan Snyder,Almeera Lateef,Alex Drohan,Mathew J. Gregoski,Virginia R. Barton,Dirk M. Elston
出处
期刊:JAMA Dermatology [American Medical Association]
卷期号:159 (5): 488-488 被引量:45
标识
DOI:10.1001/jamadermatol.2023.0205
摘要

Importance: Disseminated superficial actinic porokeratosis (DSAP) is an inherited or sporadic disorder of keratinization associated with germline variations. There is no effective standard of care therapy for DSAP, but treatment with topical lovastatin combined with cholesterol cream has shown promise. Objectives: To evaluate and compare the safety and efficacy of topical lovastatin 2% plus cholesterol 2% cream (lovastatin-cholesterol) and topical lovastatin 2% cream (lovastatin) alone in adults diagnosed with DSAP. Design, Setting, and Participants: This patient- and assessor-blinded, randomized clinical trial was conducted at the Medical University of South Carolina between August 3, 2020, and April 28, 2021. Nonpregnant adults with a previous clinical or histological diagnosis of DSAP were eligible. Data were blindly analyzed after study completion. Interventions: Participants were randomized to once- or twice-daily application of either lovastatin-cholesterol cream (n = 17) or lovastatin cream (n = 14) to symptomatic regions for 12 weeks. Main Outcomes and Measures: The primary efficacy measure was the effect of the treatment on DSAP at the end of treatment (12 weeks) as measured by the DSAP General Assessment Severity Index (DSAP-GASI; scored from 0-4, with 0 indicating clear and 4 indicating severe). Treatment efficacy was based on investigator-standardized photographs provided by the participants because of the need for evaluation via telehealth during the COVID-19 pandemic. Secondary efficacy measures included patient-reported outcomes, application frequency, and adverse events (AEs). Results: Of the 87 participants screened, 32 were enrolled. One participant randomized to receive lovastatin-cholesterol did not receive the intervention, leaving 17 participants (mean [range] age, 59.2 [40-83] years; 13 females [76.5%]; all White) allocated to receive lovastatin-cholesterol treatment and 14 participants (13 female [92.9%]; mean (range) age, 53.7 [33-71] years; all White) to receive lovastatin treatment. Twelve participants in each treatment group qualified for the analysis. Disease severity decreased from week 1 to week 12 by 50.0% (from 3.08 [95% CI, 2.57-3.60] to 1.54 (95% CI, 1.04-2.05] points on the DSAP-GASI; P < .001) in the lovastatin-cholesterol group and 51.4% (from 2.92 [95% CI, 2.40-3.43] to 1.50 [95% CI, 0.99-2.01] points; P < .001) in the lovastatin group. There was no significant difference between the treatment groups according to application frequency at the end of 12 weeks. Adverse events reported included myalgia (n = 2), elevation in the creatine kinase level (n = 1), application discomfort (n = 4), and rash (n = 1). No serious AEs occurred, and all participants with an AE were able to complete the study. Conclusions and Relevance: This randomized clinical trial found improvements in DSAP severity in both treatment groups, without serious AEs, indicating a limited benefit with the addition of cholesterol. These results suggest that lovastatin cream may be a new primary treatment option for patients diagnosed with DSAP. Trial Registration: ClinicalTrials.gov Identifier: NCT04359823.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
在这完成签到,获得积分10
刚刚
adi完成签到 ,获得积分10
刚刚
star完成签到,获得积分10
1秒前
思念是什么味道完成签到,获得积分10
1秒前
工作热情仔的应助被yyds采纳,获得30
1秒前
冲就完了发布了新的文献求助10
1秒前
李健的应助被肉丸子采纳,获得10
1秒前
mkl发布了新的文献求助10
1秒前
1秒前
2秒前
Caicai发布了新的文献求助10
2秒前
obito完成签到,获得积分10
2秒前
阿白完成签到 ,获得积分10
2秒前
阳光海豚完成签到,获得积分10
3秒前
GuSiwen完成签到,获得积分10
3秒前
玉玉鼠完成签到,获得积分10
3秒前
秋风的应助被CJW采纳,获得20
3秒前
3秒前
一一完成签到 ,获得积分10
3秒前
4秒前
灭法者驳回了QDU的应助
5秒前
001完成签到,获得积分10
5秒前
Hello的应助被皮卡路采纳,获得10
5秒前
WxChen完成签到,获得积分10
5秒前
六六发布了新的文献求助10
5秒前
山海不远发布了新的文献求助30
6秒前
ding的应助被动听冬寒采纳,获得10
6秒前
沉静的煎蛋完成签到,获得积分10
6秒前
情怀的应助被顶刊相见采纳,获得10
6秒前
song完成签到,获得积分10
6秒前
6秒前
洋洋洋完成签到,获得积分0
6秒前
6秒前
CodeCraft的应助被hupo采纳,获得10
7秒前
细心黎昕发布了新的文献求助10
7秒前
efls完成签到,获得积分10
8秒前
852的应助被CYH采纳,获得10
8秒前
tyx完成签到,获得积分10
8秒前
access完成签到,获得积分10
8秒前
小低调发布了新的文献求助10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180531
求助须知:如何正确求助?哪些是违规求助? 9570507
关于积分的说明 21812974
捐赠科研通 7776619
什么是DOI,文献DOI怎么找? 3433286
关于科研通互助平台的介绍 2557539
邀请新用户注册赠送积分活动 2479185